Antengene Announces First Patient Dosed in Phase II Trial of ATG-008 (Onatasertib) in Patients with…
Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class…
Read More...
Read More...